We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Results of Clinical Study into the Retrospective Analysis of Colon Cancer Patients Published
News

Results of Clinical Study into the Retrospective Analysis of Colon Cancer Patients Published

Results of Clinical Study into the Retrospective Analysis of Colon Cancer Patients Published
News

Results of Clinical Study into the Retrospective Analysis of Colon Cancer Patients Published

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Results of Clinical Study into the Retrospective Analysis of Colon Cancer Patients Published"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Specifically the study, published by Horizon Discovery co-founder Professor Alberto Bardelli (Universityof Torino) and SAB member Professor Sabine Tejpar (University of Leuven), found that patients carrying a particular and relatively common (20% of mutant KRAS cases) form of mutant KRAS (the G13D variant) are not resistant to Erbitux therapy, as was previously assumed. These findings, confirmed in the in-vivo and clinical patient samples, suggest that more detailed analysis of specific mutant KRAS variants in prospective clinical trials are required to reveal the true impact of specific mutant KRAS variants on patients receiving Erbitux therapy.  

A copy of the publication is available to view online.  

Advertisement